Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia

References

• Endrich B, Reinhold HS, Gross JF, Intaglietta M. Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 1979; 62:387 - 95; PMID: 283271
   PubMed Web of Science ®Google Scholar
• Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008; 8:180 - 92; http://dx.doi.org/10.1038/nrc2344; PMID: 18273037
   PubMed Web of Science ®Google Scholar
• Yotnda P, Wu D, Swanson AM. Hypoxic tumors and their effect on immune cells and cancer therapy. Methods Mol Biol 2010; 651:1 - 29; http://dx.doi.org/10.1007/978-1-60761-786-0_1; PMID: 20686957
   PubMedGoogle Scholar
• Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38 - 47; http://dx.doi.org/10.1038/nrc704; PMID: 11902584
   PubMed Web of Science ®Google Scholar
• Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007; 9:1237 - 94; http://dx.doi.org/10.1089/ars.2007.1623; PMID: 17571959
   PubMed Web of Science ®Google Scholar
• Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13:Suppl 3 21 - 6; http://dx.doi.org/10.1634/theoncologist.13-S3-21; PMID: 18458121
   PubMed Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408 - 16; PMID: 9537241
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8:425 - 37; http://dx.doi.org/10.1038/nrc2397; PMID: 18500244
   PubMed Web of Science ®Google Scholar
• Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011; 14:191 - 201; http://dx.doi.org/10.1016/j.drup.2011.03.001; PMID: 21466972
   PubMed Web of Science ®Google Scholar
• Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007; 32:517 - 30; http://dx.doi.org/10.1007/s12038-007-0051-y; PMID: 17536171
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer 2009; 100:1523 - 9; http://dx.doi.org/10.1038/sj.bjc.6605066; PMID: 19401686
   PubMed Web of Science ®Google Scholar
• Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004; 10:47 - 51; http://dx.doi.org/10.1016/j.molmed.2003.12.005; PMID: 15106614
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009; 29:797 - 807; PMID: 19414312
   PubMed Web of Science ®Google Scholar
• Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B, et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 2008; 14:1831 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-07-1607; PMID: 18347186
   PubMed Web of Science ®Google Scholar
• Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004; 10:8077 - 84; http://dx.doi.org/10.1158/1078-0432.CCR-04-1212; PMID: 15585643
   PubMed Web of Science ®Google Scholar
• Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 2003; 9:3749 - 55; PMID: 14506167
   PubMed Web of Science ®Google Scholar
• Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63:8984 - 95; PMID: 14695217
   PubMed Web of Science ®Google Scholar
• Harashima K, Akimoto T, Nonaka T, Tsuzuki K, Mitsuhashi N, Nakano T. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor. Int J Radiat Biol 2005; 81:63 - 76; http://dx.doi.org/10.1080/09553000400029460; PMID: 15962764
   PubMed Web of Science ®Google Scholar
• Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, et al. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Br J Cancer 2009; 100:334 - 43; http://dx.doi.org/10.1038/sj.bjc.6604855; PMID: 19142186
   PubMed Web of Science ®Google Scholar
• Kabakov AE, Makarova YM, Malyutina YV. Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin. Int J Radiat Oncol Biol Phys 2008; 71:858 - 65; http://dx.doi.org/10.1016/j.ijrobp.2008.02.034; PMID: 18410996
   PubMed Web of Science ®Google Scholar
• Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 2003; 79:973 - 80; http://dx.doi.org/10.1080/09553000310001626135; PMID: 14713575
   PubMed Web of Science ®Google Scholar
• Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of hsp90 compromises the DNA damage response to radiation. Cancer Res 2006; 66:9211 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-06-2181; PMID: 16982765
   PubMed Web of Science ®Google Scholar
• Stingl L, Stühmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010; 102:1578 - 91; http://dx.doi.org/10.1038/sj.bjc.6605683; PMID: 20502461
   PubMed Web of Science ®Google Scholar
• Okui T, Shimo T, Hassan NM, Fukazawa T, Kurio N, Takaoka M, et al. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. Anticancer Res 2011; 31:1197 - 204; PMID: 21508365
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, et al. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 2011; 102:1388 - 95; http://dx.doi.org/10.1111/j.1349-7006.2011.01944.x; PMID: 21453385
   PubMed Web of Science ®Google Scholar
• Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T, Ohyashiki K. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene 2011; 30:2789 - 97; http://dx.doi.org/10.1038/onc.2011.3; PMID: 21278787
   PubMed Web of Science ®Google Scholar
• Hammond EM, Dorie MJ, Giaccia AJ. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 2003; 278:12207 - 13; http://dx.doi.org/10.1074/jbc.M212360200; PMID: 12519769
   PubMed Web of Science ®Google Scholar
• Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, et al. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 2004; 64:3486 - 90; http://dx.doi.org/10.1158/0008-5472.CAN-03-1788; PMID: 15150102
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Hao Z, Rait A, Ho CW, Chang EH. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 1997; 230:196 - 201; http://dx.doi.org/10.1006/bbrc.1996.5922; PMID: 9020045
   PubMed Web of Science ®Google Scholar
• Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, et al. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 2007; 6:70 - 5; http://dx.doi.org/10.4161/cbt.6.1.3550; PMID: 17172824
   PubMed Web of Science ®Google Scholar
• Kaluzová M, Pastoreková S, Pastorek J, Kaluz S. P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells. Biochim Biophys Acta 2000; 1491:20 - 6; PMID: 10760566
   PubMed Web of Science ®Google Scholar
• Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008; 7:1985 - 92; http://dx.doi.org/10.1158/1535-7163.MCT-07-2104; PMID: 18645008
   PubMed Web of Science ®Google Scholar
• Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14:250 - 62; http://dx.doi.org/10.1016/j.ccr.2008.08.002; PMID: 18772114
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858 - 68; http://dx.doi.org/10.1074/jbc.273.10.5858; PMID: 9488723
   PubMed Web of Science ®Google Scholar
• Djuzenova CS, Flentje M. Characterization of Fanconi anemia fibroblasts in terms of clonogenic survival and DNA damage assessed by the Comet assay. Med Sci Monit 2002; 8:BR421 - 30; PMID: 12388916
   PubMedGoogle Scholar
• Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002; 22:1834 - 43; http://dx.doi.org/10.1128/MCB.22.6.1834-1843.2002; PMID: 11865061
   PubMed Web of Science ®Google Scholar
• Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, Drysdale MJ, et al. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther 2010; 9:906 - 19; http://dx.doi.org/10.1158/1535-7163.MCT-10-0055; PMID: 20371713
   PubMed Web of Science ®Google Scholar
• Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008; 10:R33; http://dx.doi.org/10.1186/bcr1996; PMID: 18430202
   PubMed Web of Science ®Google Scholar
• McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008; 7:3256 - 64; http://dx.doi.org/10.1158/1535-7163.MCT-08-0157; PMID: 18852129
   PubMed Web of Science ®Google Scholar
• Messaoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 2008; 8:761 - 82; PMID: 18855578
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 2009; 12:17 - 27; http://dx.doi.org/10.1016/j.drup.2008.12.002; PMID: 19179103
   PubMed Web of Science ®Google Scholar
• Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009; 52:4794 - 809; http://dx.doi.org/10.1021/jm900357y; PMID: 19610616
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68:2850 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-07-5256; PMID: 18413753
   PubMed Web of Science ®Google Scholar
• Olive PL, Banáth JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004; 58:331 - 5; http://dx.doi.org/10.1016/j.ijrobp.2003.09.028; PMID: 14751500
   PubMed Web of Science ®Google Scholar
• Bencokova Z, Kaufmann MR, Pires IM, Lecane PS, Giaccia AJ, Hammond EM. ATM activation and signaling under hypoxic conditions. Mol Cell Biol 2009; 29:526 - 37; http://dx.doi.org/10.1128/MCB.01301-08; PMID: 18981219
   PubMed Web of Science ®Google Scholar
• Djuzenova CS, Güttler T, Berger S, Katzer A, Flentje M. Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment. Cancer Biol Ther 2008; 7:364 - 73; http://dx.doi.org/10.4161/cbt.7.3.5363; PMID: 18075304
   PubMed Web of Science ®Google Scholar
• Vordermark D, Kaffer A, Riedl S, Katzer A, Flentje M. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 2005; 61:1197 - 207; http://dx.doi.org/10.1016/j.ijrobp.2004.11.031; PMID: 15752902
   PubMed Web of Science ®Google Scholar
• Muslimovic A, Ismail IH, Gao Y, Hammarsten O. An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells. Nat Protoc 2008; 3:1187 - 93; http://dx.doi.org/10.1038/nprot.2008.93; PMID: 18600224
   PubMed Web of Science ®Google Scholar
• Mahrhofer H, Bürger S, Oppitz U, Flentje M, Djuzenova CS. Radiation induced DNA damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Radiat Oncol Biol Phys 2006; 64:573 - 80; http://dx.doi.org/10.1016/j.ijrobp.2005.09.037; PMID: 16414372
   PubMed Web of Science ®Google Scholar
• Djuzenova CS, Sukhorukov VL, Klöck G, Arnold WM, Zimmermann U. Effect of electric field pulses on the viability and on the membrane-bound immunoglobulins of LPS-activated murine B-lymphocytes: correlation with the cell cycle. Cytometry 1994; 15:35 - 45; http://dx.doi.org/10.1002/cyto.990150107; PMID: 8162823
   PubMedGoogle Scholar